Millipore Sigma Vibrant Logo

マルチスクリーン(MultiScreen)HTS Elispot用フィルタープレート

Elispot MultiScreen®HTS Filter Plates demonstrate improved spot recovery and spot definition

関連資料

概要

仕様

ご注文情報

Go
マルチスクリーンHTS フィルタープレート並べ替えとフィルターをクリアする Show Filter
カタログ番号説明材質無菌性デバイス材カラーコードパッケージ
MSHAS4510マルチスクリーン(MultiScreen)HTS HA, 0.45 µm, 透明, 滅菌済 •Mixed Cellulose Esters (MCE) 滅菌済 スチレン 透明 10 価格&在庫状況を表示
MSIPS4W10マルチスクリーン(MultiScreen)HTS IP, 0.45 µm, 白色, 滅菌済 疎水性PVDF 滅菌済 アクリル 白色 10 価格&在庫状況を表示
MSIPN4510マルチスクリーン(MultiScreen)HTS IP, 0.45 µm, 透明, 非滅菌 疎水性PVDF 非滅菌 アクリル 透明 10 価格&在庫状況を表示
MSIPN4W50マルチスクリーン(MultiScreen)HTS IP, 0.45 µm, 白色, 非滅菌 疎水性PVDF 非滅菌 アクリル 白色 50 価格&在庫状況を表示
MSIPN4550マルチスクリーン(MultiScreen)HTS IP, 0.45 µm, 透明, 非滅菌 疎水性PVDF 非滅菌 アクリル 透明 50 価格&在庫状況を表示
MSIPS4510マルチスクリーン(MultiScreen)HTS IP, 0.45 µm, 透明, 滅菌済 疎水性PVDF 滅菌済 アクリル 透明 10 価格&在庫状況を表示

トップに戻る

マルチスクリーンフィルタープレート並べ替えとフィルターをクリアする Show Filter
カタログ番号説明材質無菌性デバイス材カラーコードパッケージ
MAIPS4510マルチスクリーン(MultiScreen)-IP, 0.45 µm, 透明, 滅菌済 疎水性PVDF 滅菌済 アクリル 透明 10 価格&在庫状況を表示
S2EM004M99マルチスクリーン(MultiScreen)-IP, 0.45 µm, 白色, 滅菌済 疎水性PVDF 滅菌済 アクリル 白色 10 価格&在庫状況を表示
MAIPSWU10マルチスクリーン(MultiScreen)-IP アンダードレイン無し、0.45μm、白色、滅菌済 疎水性PVDF 滅菌済 アクリル 白色 10 価格&在庫状況を表示
MAHAS4510マルチスクリーン(MultiScreen)-HA, 0.45 µm, 透明, 滅菌済 •Mixed Cellulose Esters (MCE) 滅菌済 スチレン 透明 10 価格&在庫状況を表示

トップに戻る

アクセサリー並べ替えとフィルターをクリアする Show Filter
カタログ番号説明パッケージ
MATAHCL00マルチスクリーン(MultiScreen) シーリング テープ, 透明, 非滅菌 100 価格&在庫状況を表示
M8IPFRAMEMultiScreenHTS Support Frame 10 価格&在庫状況を表示

トップに戻る

マルチスクリーンHTS 8ウェルストリップ並べ替えとフィルターをクリアする Show Filter
カタログ番号説明材質無菌性デバイス材カラーコードパッケージ
M8IPS4510MultiScreenHTS IP Filter Plate, 0.45 µm, 8-Well Strips, clear, non-sterile 疎水性PVDF 非滅菌 アクリル 透明 10 価格&在庫状況を表示

トップに戻る

Elispot Matched Antibody Pairs並べ替えとフィルターをクリアする Show Filter
カタログ番号説明パッケージ
ELI-006-HIL-5 ELISPOT Antibody Pair, Human 1 kit 価格&在庫状況を表示
ELI-008-MIL-6 ELISPOT Antibody Pair, Mouse 1 kit 価格&在庫状況を表示

トップに戻る

Documentation

参考資料

参考資料の概要アプリケーション
Simultaneous detrection of multiple cytokines in ELISPOT assays.
Palzer S. Bailey T., Hartnett C., Grant A., Tsang M., Kalyuzhny AE.
Methods Mol Biol. 2005; 305:273-88  2005

ELISPOT Assays
The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity
Kimberly Shafer-Weaver, Thomas Sayers, Susan Strobl, Eric Derby, Tracy Ulderich, Michael Baseler and Anatoli Malyguine
Journal of Translational Medicine 2003, 1:14     doi:10.1186/1479-5876-1-14  2003

ELISPOT Assays
Protein kinase C [beta]II activation induces angiotensin converting enzyme expression in neonatal rat cardiomyocytes.
Yuke Zhang, Laura J. Bloem, Lan Yu, Thomas B. Estridge, Philip W. Iversen, Christine E. McDonald, James P. Schrementi, XuShan Wang, Chris J. Vlahos and Jian Wang
Cardiovascular Research 57 (1): 139-146  2003

Enzyme Assays
Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity.
Hongxun Sang, Vladimir M. Pisarev, Corey Munger, Simon Robinson, Jennifer Chavez, Lori Hatcher, Prahlad Parajuli, Yajun Guo and James E. Talmadge
Vaccine 21 (21-22): 3019-3029  2003

ELISPOT Assays
CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.
Jennifer L. Harcourt, Michael P. Brown, Larry J. Anderson and Ralph A. Tripp
Vaccine 21 (21-22): 2964-2979  2003

ELISPOT Assays
Rectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization.
Leslie Ann Mitchell and Eithan Galun
Vaccine 21 (13-14): 1527-1538  2003

ELISPOT Assays
A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design.
Roshni Sundaram, Yiping Sun, Christopher M. Walker, Francois A. Lemonnier, Steven Jacobson and Pravin T. P. Kaumaya
Vaccine 21 (21-22): 2767-2781  2003

ELISPOT Assays
Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
Wai Ming Li, Wieslawa H. Dragowska, Marcel B. Bally and Marie-Paule Schutze-Redelmeier
Vaccine 21 (23): 3319-3329  2003

ELISPOT Assays
The role of lipopolysaccharide in T-cell responses following DNA vaccination.
William G. Hawkins, Jiri Trcka, Neil Segal, Nathalie E. Blachere, Jason S. Gold, Yoichi Moroi, Wilbur B. Bowne, Jonathan J. Lewis, Jedd D. Wolchok and Alan N. Houghton
Vaccine 21 (13-14): 1548-1553  2003

ELISPOT Assays
A quantitive, highly sensitive cell-based infectivity assay for mouse scrapie prions.
P.-C. Klöhn, L. Stoltze, E. Flechsig, M. Enari, and C. Weissmann
PNAS 100 (D6920): 11666-11671  2003

ELISPOT Assays

FAQ(よくある質問と回答)

質問回答
When performing an ELISpot assay should MultiScreen plates with Immobilon-P membrane (MAIP and MSIP) be initially pre-wet with alcohol(methanol/ethanol)?Yes. Wetting the membrane with 15 µL alcohol followed by two to three washes with sterile PBS will allow the antibody more intimate contact with the membrane. Do not vacuum the alcohol through the underdrain, rather it should be flicked out. Once the membrane is pre-wet with alcohol, do not allow it to dry for the duration of the assay.
Should MultiScreen MAHA and MSHA ELISpot plates with MCE membranes be initially pre-wet with alcohol or sterile buffer?No. Neither is necessary. Methanol will dissolve the mixed-cellulose ester membrane. PBS is no longer needed. Membrane improvements ensure instant wetting of the membrane.
We are looking to coat MultiScreen ELISpot plates with primary antibody and store them. Do you have a recommended protocol?After coating with primary antibody overnight at 4°C, wash twice with 150µL sterile Milli-Q® water. Dry plates thoroughly under sterile conditions and store for up to one week at 4°C. If longer storage is desired, the plates should be washed as previously described and then blocked (150µL/well media, 37°C, 2hr). Following blocking, wash 2x with 150µL sterile Milli-Q. Dry as before and store desiccated. Ab activity may diminish over time - especially in the event that the plates have not been blocked. Millipore has not determined shelf-life for either protocol as performance stability is likely to depend largely on the properties of the specific antibody under investigation.